The Sterol Regulatory Element-Binding Transcription Factor 2 (SREBF2) antibody is a key tool for studying the role of SREBF2. a master regulator of cholesterol homeostasis. SREBF2. a member of the SREBP family, is a membrane-bound transcription factor synthesized as an inactive precursor in the endoplasmic reticulum (ER). Under low cholesterol conditions, it undergoes proteolytic cleavage, releasing its active N-terminal domain, which translocates to the nucleus to activate genes involved in cholesterol synthesis (e.g., HMGCR, LDLR) and uptake.
SREBF2 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect SREBF2 expression, localization, and processing. These antibodies often target specific epitopes, such as the precursor form (∼125 kDa) or the mature nuclear form (∼68 kDa), aiding research on lipid metabolism disorders, cardiovascular diseases, and metabolic syndromes. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple isoforms but require validation to avoid cross-reactivity with SREBF1. a related protein regulating fatty acid synthesis.
Studies using SREBF2 antibodies have elucidated its dysregulation in conditions like atherosclerosis, obesity, and cancer, as well as its interaction with pathways such as mTOR and insulin signaling. Proper antibody selection is critical, considering post-translational modifications, tissue-specific expression, and experimental conditions affecting SREBF2 activation.